270P First-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with a homologous recombination repair (HRR) germline pathogenic variant (PV) and breast cancer (BC): Clinical outcomes and mechanisms of resistance | Publicación